The tests will be performed in the US and Flanders/Belgium on 1,045 healthy adults between 18 and 55 years old as well as a number of people aged 65+. At the same time, Johnson & Johnson is negotiating to establish partners globally and continuing its efforts to invest in its technology and vaccine production capacity.
The test will be a randomized, double-blind study with a placebo control group. This means that one group in the study is given the vaccine and a control group receives a placebo, a non-active agent. Double-blind indicates that neither the researchers nor the participants know who will receive a placebo and who will receive the real vaccine.